Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
74°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gain Therapeutics, Inc.
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
August 08, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
August 01, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
June 28, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
June 27, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
June 27, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 25, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
June 13, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Proposed Public Offering
June 13, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
May 30, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
May 14, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
April 24, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
April 08, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
April 01, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
March 26, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Present at Public Ventures Discovery Day
March 15, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
March 05, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
February 27, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
February 14, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
February 06, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
February 06, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
January 31, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
January 02, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
December 04, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
December 01, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
November 29, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
November 24, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
November 21, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Proposed Public Offering
November 20, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
November 14, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
October 04, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GANX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.